Press Releases

Date	Title
December 13, 2018	Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
November 19, 2018	Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome
November 1, 2018	Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
October 25, 2018	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 24, 2018	Judge Denies Teva Pharmaceuticals’ Motion to Dismiss Corcept Therapeutics’ Allegations of Patent Infringement
October 1, 2018	Corcept Therapeutics Receives Orphan Designation for Relacorilant as Treatment for Pancreatic Cancer
August 9, 2018	Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update
August 2, 2018	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
June 4, 2018	Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting
May 16, 2018	Corcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual Congress